일라이릴리 맞춤형 치료제 전략

목차

1. Recommendations
2. Initial Approach: Pilot TT in Oncology TA
3. Proactively Leading on Necessary Ecosystem Adaptations
4. Overview of R&D-Focused Architecture
5. Driving Change Management
6. Implementation Alternatives

본문내용

1) Begin more deeply exploring tailoring
Recommended Actions:
- Reaffirm that TT is voluntary in all TAs, but “encourage” more forcefully
- Launch full-scale TT pilot in Oncology TA

To transition to TT, Lilly must more strongly encourage TAs to consider tailoring. And because the transition is not an urgent threat but an opportunity, Lilly should prioritize getting it right, rather than going too fast, by piloting TT—first in Oncology and then leveraging lessons to subsequently implement more effectively in the other TAs.

참고 자료

없음